当前位置:首页 - 行情中心 - 康泰生物(300601) - 财务分析 - 现金流量表

康泰生物

(300601)

  

流通市值:168.46亿  总市值:208.98亿
流通股本:9.00亿   总股本:11.17亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,227,569,112.81544,167,223.262,796,306,483.641,911,831,279.91
  收到的税费返还---0
  收到其他与经营活动有关的现金55,930,211.5137,579,608.67137,312,136.94115,886,525.01
  经营活动现金流入小计1,283,499,324.32581,746,831.932,933,618,620.582,027,717,804.92
  购买商品、接受劳务支付的现金173,472,752.5891,121,906.96370,479,559.48290,421,678.04
  支付给职工以及为职工支付的现金267,864,630.99139,614,676533,609,185.01416,328,473.45
  支付的各项税费65,085,077.0531,820,790.28122,503,462.4481,749,140.22
  支付其他与经营活动有关的现金701,480,111.3365,492,876.671,303,776,708.821,003,013,262.35
  经营活动现金流出小计1,207,902,571.92628,050,249.912,330,368,915.751,791,512,554.06
  经营活动产生的现金流量净额75,596,752.4-46,303,417.98603,249,704.83236,205,250.86
二、投资活动产生的现金流量:
  收回投资收到的现金834,000,00060,000,000790,000,000710,000,000
  取得投资收益收到的现金33,674,638.3688,602.7456,742,843.3448,571,260.26
  处置固定资产、无形资产和其他长期资产收回的现金净额46,8001,22016,151,556.46342,039.17
  投资活动现金流入小计867,721,438.3660,089,822.74862,894,399.8758,913,299.43
  购建固定资产、无形资产和其他长期资产支付的现金159,983,023.59125,315,698.65472,181,999.18379,375,185.54
  投资支付的现金710,000,001-947,400,000937,400,000
  投资活动现金流出小计869,983,024.59125,315,698.651,419,581,999.181,316,775,185.54
  投资活动产生的现金流量净额-2,261,586.23-65,225,875.91-556,687,599.38-557,861,886.11
三、筹资活动产生的现金流量:
  取得借款收到的现金39,900,00025,500,000212,621,632.83202,521,632.83
  收到其他与筹资活动有关的现金84,357.7884,357.7811,605,349.4211,605,349.42
  筹资活动现金流入小计39,984,357.7825,584,357.78224,226,982.25214,126,982.25
  偿还债务支付的现金223,091,749.54122,991,749.54743,152,554.23611,535,953.51
  分配股利、利润或偿付利息支付的现金101,464,255.51692,363.7256,620,086.84254,313,016.77
  支付其他与筹资活动有关的现金1,463,146.63842,025.0625,212,258.9524,682,926.38
  筹资活动现金流出小计326,019,151.68124,526,138.31,024,984,900.02890,531,896.66
  筹资活动产生的现金流量净额-286,034,793.9-98,941,780.52-800,757,917.77-676,404,914.41
四、汇率变动对现金及现金等价物的影响-205,643.66-62,987.62-60,732.33-186,029.74
五、现金及现金等价物净增加额-212,905,271.39-210,534,062.03-754,256,544.65-998,247,579.4
  加:期初现金及现金等价物余额416,069,254.45416,069,254.451,170,325,799.11,170,325,799.1
  期末现金及现金等价物余额203,163,983.06205,535,192.42416,069,254.45172,078,219.7
补充资料:
  净利润37,600,910.41-201,553,722.8-
  资产减值准备93,665,145.75-231,519,516.32-
  固定资产和投资性房地产折旧177,103,275.73-281,785,121.33-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧177,103,275.73-281,785,121.33-
  无形资产摊销22,193,837.92-35,453,043.89-
  长期待摊费用摊销22,497,376.09-36,217,043.5-
  处置固定资产、无形资产和其他长期资产的损失365,901.81-8,415,471.25-
  固定资产报废损失1,929,965.86-563,629.84-
  公允价值变动损失-58,300--1,380,868.09-
  财务费用15,712,158.75-34,104,963.89-
  投资损失-99,250.45--465,020.57-
  递延所得税-37,722,832.42--57,932,839.87-
  其中:递延所得税资产减少-35,306,967.37--65,715,398.85-
    递延所得税负债增加-2,415,865.05-7,782,558.98-
  存货的减少6,306,540.69--79,029,008.63-
  经营性应收项目的减少-148,527,495.63--20,261,585.89-
  经营性应付项目的增加-143,174,781.72--183,761,170.95-
  其他--86,990,899.08-
  现金的期末余额203,163,983.06-416,069,254.45-
  减:现金的期初余额416,069,254.45-1,170,325,799.1-
  现金及现金等价物的净增加额-212,905,271.39--754,256,544.65-
公告日期2025-08-222025-04-212025-04-212024-10-26
审计意见(境内)标准无保留意见
TOP↑